Imitrex (Sumatriptan) is an antimigraine medicine.

Imitrex (Sumatriptan) is an antimigraine medicine.

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes.

GST alone was used as a negative control in these experiments.

Exceptions include reports of paresthesia (5% IMITREX injection, 0% placebo), nausea and vomiting (4% IMITREX injection, 0% placebo), and bronchospasm (1% IMITREX injection, 0% placebo).

Sumatriptan — There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a SSRI and sumatriptan.

Exceptions include reports of paresthesia (5% sumatriptan, 0% placebo), nausea and vomiting (4% sumatriptan, 0% placebo), and bronchospasm (1% sumatriptan, 0% placebo).

Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a SSRI and sumatriptan.

DNA alone was employed as a negative control in this experiment.

Sumatriptan: Weakness, hyperreflexia, and incoordination following the use of an SSRI and sumatriptan.

Generic Imitrex (Sumatriptan) is an antimigraine medicine.

Acute pathological laughter induced by sumatriptan.

Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with sumatriptan tablets.

Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of an SSRI and sumatriptan.